Medicine and Dentistry
Uveitis
100%
Pancreas Adenocarcinoma
91%
Asthma
81%
Disease
68%
Steroid Treatment
57%
Pancreas Cancer
52%
Papillomavirus Infection
52%
Macular Edema
48%
Fluocinolone Acetonide
47%
Arm
46%
Systemic Therapy
45%
Visual Acuity
44%
Human Immunodeficiency Virus
42%
Placebo
39%
Overall Survival
37%
Wart Virus
36%
Infection
35%
Pancreas Tumor
34%
Hazard Ratio
33%
Randomized Clinical Trial
31%
Cohort Analysis
29%
Biological Marker
26%
Neoplasm
25%
Tumor Vaccine
25%
Gemcitabine
25%
Chronic Obstructive Pulmonary Disease
25%
Stereotactic Body Radiation Therapy
25%
Quality of Life
24%
Symptom
23%
Optical Coherence Tomography
22%
Implant
22%
Cyclophosphamide
21%
Granulocyte Macrophage Colony Stimulating Factor
20%
Cataract Surgery
19%
Cerebral Hemorrhage
18%
Methylation
18%
Azacitidine
18%
Best Corrected Visual Acuity
18%
Immunotherapy
18%
Phase II Trials
17%
Alteplase
17%
Clinical Trial
17%
Adolescent
17%
Low Drug Dose
17%
Evacuation
16%
Nivolumab
16%
National Eye Institute Visual Function Questionnaire
16%
Dexamethasone
16%
Minimally Invasive Surgery
16%
Ipilimumab
16%
Keyphrases
Uveitis
65%
Confidence Interval
51%
Oral Human Papillomavirus
51%
Steroid Treatment
41%
Allogeneic
40%
Panuveitis
40%
Overall Survival
40%
Asthma
39%
Treatment Trials
39%
Risk Factors
37%
Pancreatic Adenocarcinoma
36%
Visual Acuity
34%
Systemic Therapy
33%
Therapeutic Vaccine
33%
Papillomavirus Infections
31%
Phase II Study
30%
Fluocinolone Acetonide Implant
29%
Granulocyte Colony-stimulating Factor (G-CSF)
29%
Pancreatic Ductal Adenocarcinoma
28%
Uveitic Macular Edema
27%
Pancreatic Cancer
27%
Gemcitabine
25%
Step-down
25%
HPV16
25%
Macular Edema
22%
Randomized Clinical Trial
22%
Metastatic Pancreatic Ductal Adenocarcinoma
21%
Pancreatic Tumor Cells
21%
Cataract Surgery
21%
High Risk
20%
Phase II Trial
18%
Hazard Ratio
18%
Best-corrected Visual Acuity
16%
VFQ-25
16%
Pancreatic Tumor
16%
Neoadjuvant
16%
Systemic Anti-inflammatory Therapy
16%
Nivolumab
16%
Pancreas
16%
Long-acting beta-agonists
16%
Ipilimumab
16%
Seropositivity
16%
Obesity
16%
Stereotactic Body Radiation Therapy
16%
Disease-free Survival
15%
Asthma Symptoms
15%
Clinical Trials
14%
Adjusted Hazard Ratio
14%
Uveitic
14%
Cyclophosphamide
14%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
75%
Pancreas Adenocarcinoma
71%
Disease
58%
Uveitis
43%
Pancreas Cancer
43%
Neoplasm
34%
Overall Survival
34%
Chemotherapy
30%
Malignant Neoplasm
27%
Randomized Clinical Trial
27%
Pancreas Tumor
27%
Placebo
26%
Tumor Vaccine
25%
Human Papillomavirus
24%
Macular Edema
23%
Papillomavirus Infection
22%
Infection
21%
Granulocyte Macrophage Colony Stimulating Factor
20%
HIV
19%
Phase II Trials
18%
Multiple Sclerosis
16%
Dexamethasone
16%
Gemcitabine
16%
Ipilimumab
16%
Chronic Obstructive Lung Disease
16%
Beta Adrenergic Receptor Stimulating Agent
16%
Chemoradiation Therapy
16%
Progression Free Survival
15%
Immunotherapy
14%
Steroid Treatment
13%
Fluorouracil
11%
Clinical Trial
11%
Mesothelin
11%
Azacitidine
11%
Vitamin D
11%
Fluocinolone Acetonide
10%
Methacholine
10%
Symptom
10%
Respiratory Tract Inflammation
9%
Cholecalciferol
9%
Biological Marker
9%
Histone Deacetylase Inhibitor
8%
Antizyme
8%
Isoflavone
8%
Cytokine
8%
Triamcinolone
8%
Methotrexate
8%
Neutropenia
8%
Fibrinolytic Agent
8%
Adenocarcinoma
8%
